Human papillomavirus status and p16INK4A expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia

Cancer Epidemiology

Volumn 39, Issue 2, 2015, Pages 174-181

  Antonsson, Annika ^a   Neale, Rachel E ^a   Boros, Samuel ^b   Lampe, Guy ^b   Coman, William B ^b   Pryor, David I ^b   Porceddu, Sandro V ^b   Whiteman, David C ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cyclin D1; Human papillomavirus DNA tests; Immunohistochemistry; P16(INK4A); Papillomavirus infections; Risk factors; Smoking; Squamous cell carcinoma of the head and neck

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; AUSTRALIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HYPOPHARYNX; IMMUNOHISTOCHEMISTRY; LARYNX; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOUTH CAVITY; OROPHARYNX; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SMOKING; WART VIRUS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; SQUAMOUS CELL CARCINOMA;

AUSTRALIA; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; QUEENSLAND; RISK FACTORS; SMOKING;

EID: 84926141193     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.01.010     Document Type: Article

References (38)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
4. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11:9-22.
5. Elwood J.M., Youlden D.R., Chelimo C., Ioannides S.J., Baade P.D. Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiol 2014, 38:16-21.
6. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956.
7. Hocking J.S., Stein A., Conway E.L., Regan D., Grulich A., Law M., et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011, 104:886-891.
8. Hansson B.G., Rosenquist K., Antonsson A., Wennerberg J., Schildt E.B., Bladstrom A., et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005, 125:1337-1344.
9. Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma. Int J Cancer 2009, 125:362-366.
10. Hong A.M., Grulich A.E., Jones D., Lee C.S., Garland S.M., Dobbins T.A., et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010, 28:3269-3272.
11. Kreimer A.R., Bhatia R.K., Messeguer A.L., Gonzalez P., Herrero R., Giuliano A.R. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010, 37:386-391.
12. Fischer C.A., Zlobec I., Green E., Probst S., Storck C., Lugli A., et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality. Int J Cancer 2010, 126:1256-1262.
13. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
14. Young R.J., Rischin D., Fisher R., McArthur G.A., Fox S.B., Peters L.J., et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomark Prev 2011, 20:1230-1237.
15. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995, 76:1057-1062.
16. de Roda Husman A.M., Walboomers J.M., Hopman E., Bleker O.P., Helmerhorst T.M., Rozendaal L., et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995, 46:97-102.
17. Lesnikova I., Lidang M., Hamilton-Dutoit S., Koch J. p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. Diagn Pathol 2009, 4:22.
18. Hanas J.S., Lerner M.R., Lightfoot S.A., Raczkowski C., Kastens D.J., Brackett D.J., et al. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer 1999, 86:756-763.
19. Hong A.M., Dobbins T.A., Lee C.S., Jones D., Fei J., Clark J.R., et al. Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. Int J Cancer 2011, 128:1532-1545.
20. Rodriguez-Pinilla M., Rodriguez-Peralto J.L., Hitt R., Sanchez J.J., Ballestin C., Diez A., et al. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 2004, 10:8486-8492.
21. Smith E.M., Wang D., Rubenstein L.M., Morris W.A., Turek L.P., Haugen T.H. Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomark Prev 2008, 17:421-427.
22. Gardner M.J., Altman D.G. Statistics with confidence - confidence intervals and statistical guidelines 1989, British Medical Journal, London.
23. Mork J., Lie A.K., Glattre E., Hallmans G., Jellum E., Koskela P., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001, 344:1125-1131.
24. Gillison M.L., D'Souza G., Westra W., Sugar E., Xiao W., Begum S., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008, 100:407-420.
25. Pintos J., Black M.J., Sadeghi N., Ghadirian P., Zeitouni A.G., Viscidi R.P., et al. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol 2008, 44:242-250.
26. Anaya-Saavedra G., Ramirez-Amador V., Irigoyen-Camacho M.E., Garcia-Cuellar C.M., Guido-Jimenez M., Mendez-Martinez R., et al. High association of human papillomavirus infection with oral cancer: a case-control study. Arch Med Res 2008, 39:189-197.
27. Michaud D.S., Langevin S.M., Eliot M., Nelson H.H., Pawlita M., McClean M.D., et al. High-risk HPV types and head and neck cancer. Int J Cancer 2014, 135:1653-1661. 10.1002/ijc.28811.
28. Münger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421.
29. Münger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989, 8:4099-4105.
30. Melkane A.E., Mirghani H., Auperin A., Saulnier P., Lacroix L., Vielh P., et al. HPV-related oropharyngeal squamous cell carcinomas: a comparison between three diagnostic approaches. Am J Otolaryngol 2014, 35:25-32.
31. Hafkamp H.C., Mooren J.J., Claessen S.M., Klingenberg B., Voogd A.C., Bot F.J., et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol 2009, 22:686-698.
32. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
33. Salazar C.R., Smith R.V., Garg M.K., Haigentz M., Schiff B.A., Kawachi N., et al. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment. Head Neck Pathol 2014, 8:77-87.
34. Fakhry C., Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006, 24:2606-2611.
35. Settle K., Posner M.R., Schumaker L.M., Tan M., Suntharalingam M., Goloubeva O., et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila, PA) 2009, 2:776-781.
36. Hesselink A.T., van Ham M.A., Heideman D.A., Groothuismink Z.M., Rozendaal L., Berkhof J., et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008, 46:3215-3221.
37. Smeets S.J., Hesselink A.T., Speel E.J., Haesevoets A., Snijders P.J., Pawlita M., et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007, 121:2465-2472.
38. Antonsson A., Cornford M., Perry S., Davis M., Dunne M.P., Whiteman D.C. Prevalence and risk factors for oral HPV infection in young Australians. PLOS ONE 2014, 9:e91761.